Want to see KR:101140 full AI Analyst Report?
INBIOGEN CO., Ltd. (101140) Stock Statistics & Valuation Metrics
Total Valuation
INBIOGEN CO., Ltd. has a market cap or net worth of KRW 45.98B. The enterprise value is KRW 60.32B.
- Market Cap
- KRW 45.98B
- Enterprise Value
- KRW 60.32B
Share Statistics
INBIOGEN CO., Ltd. has 10,044,217 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,044,217
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
INBIOGEN CO., Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is -2.73%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- -2.73%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 153.58M
- Profits Per Employee
- 142.04M
- Employee Count
- 41
- Asset Turnover
- 0.04
- Inventory Turnover
- 229.57
Valuation Ratios
The current PE Ratio of INBIOGEN CO., Ltd. is -1.11. INBIOGEN CO., Ltd.’s PEG ratio is -0.02.
- PE Ratio
- -1.11
- PS Ratio
- 9.01
- PB Ratio
- 0.02
- Price to FCF
- -12.63
- Price to Operating Cash Flow
- -0.63
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, INBIOGEN CO., Ltd. had revenue of 6.30B and earned 5.82B in profits. Earnings per share was 579.79.
- Revenue
- 6.30B
- Gross Profit
- -574.39M
- Operating Income
- -4.33B
- Pretax Income
- -1.42B
- Net Income
- 5.82B
- EBITDA
- -3.97B
- Earnings Per Share (EPS)
- 579.79
Cash Flow
In the last 12 months, operating cash flow was -3.64B and capital expenditures -4.10M, giving a free cash flow of -3.64B billion.
- Operating Cash Flow
- -3.64B
- Free Cash Flow
- -3.64B
- Free Cash Flow per Share
- -7292.04
Dividends & Yields
INBIOGEN CO., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.92%
- Earnings Yield
- -901.58%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- -63.85%
- 50-Day Moving Average
- 5041.10
- 200-Day Moving Average
- 7174.43
- Relative Strength Index (RSI)
- 36.47
- Average Volume (3m)
- 4,232
Important Dates
INBIOGEN CO., Ltd. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
INBIOGEN CO., Ltd. as a current ratio of 2.86, with Debt / Equity ratio of 0.74%
- Current Ratio
- 2.86
- Quick Ratio
- 2.84
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.07
- Interest Coverage Ratio
- -55.23
Taxes
In the past 12 months, INBIOGEN CO., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
INBIOGEN CO., Ltd. EV to EBITDA ratio is 8.72, with an EV/FCF ratio of -13.10.
- EV to Sales
- 9.34
- EV to EBITDA
- 8.72
- EV to Free Cash Flow
- -13.10
- EV to Operating Cash Flow
- -13.11
Balance Sheet
INBIOGEN CO., Ltd. has KRW 2.34B in cash and marketable securities with KRW 4.05B in debt, giving a net cash position of -KRW 1.71B billion.
- Cash & Marketable Securities
- KRW 2.34B
- Total Debt
- KRW 4.05B
- Net Cash
- -KRW 1.71B
- Net Cash Per Share
- -KRW 170.23
- Tangible Book Value Per Share
- KRW 283.22K
Margins
Gross margin is -10.71%, with operating margin of -76.63%, and net profit margin of -406.14%.
- Gross Margin
- -10.71%
- Operating Margin
- -76.63%
- Pretax Margin
- -406.14%
- Net Profit Margin
- -406.14%
- EBITDA Margin
- 107.14%
- EBIT Margin
- 104.46%
Analyst Forecast
The average price target for INBIOGEN CO., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -34.04%
- EPS Growth Forecast
- -139.58%
Scores
- Smart Score
- ―
- AI Score
- 44